America’s Healthcare Crisis–Part V–FDA Complicit in Crimes

fda_shoddy_reviews.jpg

FDA, a complicit partner in crimes and corrupt industry practices have resulted in an epidemic of preventable injuries and deaths. Continue reading →

Specific Anticonvulsants Increase Suicide Risk

A large-scale Harvard meta-analysis published in the Journal of the American Medical Association, is the first ever to evaluate the relationship between different anticonvulsant drugs and the risk of suicide in for patients with diverse diagnoses: " the risk was derived from the specific drug that the patient was taking and not their underlying conditions." Continue reading →

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known. Continue reading →

Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM

FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Continue reading →

Columbia Journalism Review–The Complicity of the Media in Drug Marketing

Columbia Journalism Review–The Complicity of the Media in Drug Marketing Wed, 27 Jul 2005 An excellent article in the Columbia Journalism Review examines pharmaceutical industry hype and the media’s role in helping that industry create false impressions about the safety and benefits . . . Continue reading →

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options Tue, 16 Aug 2005 A series of current articles in The Wall Street Journal, the Journal of the American Medical Association (JAMA), and the New York Times describe the . . . Continue reading →

At FDA, Changes In Name Only–Agency Puts Business interests Above Safety

At FDA, Changes In Name Only–Agency Puts Business interests Above Safety Fri, 30 Sep 2005 The sudden resignation of FDA Commissioner, Lester Crawford, after just two months in office, has prompted a bipartisan Senate investigation and requests both by the Senate committee . . . Continue reading →